Lv2
150 积分 2025-04-07 加入
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
3个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
5个月前
已完结
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
5个月前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
5个月前
已完结
P3.13.34 Tarlatamab Efficacy and Safety in Chinese Patients with Advanced Small Cell Lung Cancer: Phase 2 DeLLphi-307
7个月前
已关闭
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
7个月前
已完结
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial
7个月前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
8个月前
已完结
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer
8个月前
已关闭
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
8个月前
已完结